Skip to content

A Clinical Study Based on Questionnaire Surveys and Clinical Data to Optimize Risk Factor Analysis and Prognostic Assessment in Atrial Fibrillation Patients

A Clinical Study Based on Questionnaire Surveys and Clinical Data to Optimize Risk Factor Analysis and Prognostic Assessment in Atrial Fibrillation Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117442
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

SR group:none

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older; 2. Diagnosed with paroxysmal or persistent atrial fibrillation and undergoing surgery; 3. Voluntarily willing to participate in this study and sign the informed consent form. If the participant is unable to read or sign the informed consent form due to lack of capacity, their guardian should act on their behalf to go through the informed process and sign the consent form. If the participant is unable to read the informed consent form (e.g., illiterate participants), a witness must witness the informed process and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to anticoagulation; 2. Known severe comorbidities with an expected survival of less than 1 year; 3. Myocardial infarction (MI) within the past 3 months, or having undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI); 4. Left atrial anteroposterior diameter >55 mm; 5. LVEF <30%; 6. NYHA functional class III or IV; 7. Planned heart transplantation or other cardiac surgery within 12 months; 8. Record of thromboembolic events in the past 6 weeks; 9. Currently participating in a study evaluating other devices or drugs; 10. Acute illness, active systemic infection, or sepsis; end-stage renal disease (eGFR <15 mL/min/1.73m²) or on dialysis; terminal malignancy; 11. Other congenital anomalies or medical issues judged by the investigator to significantly prevent patient participation in this study; 12. Vulnerable populations other than illiterate or elderly individuals, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
medical data;

Countries

China

Contacts

Public ContactChenyang Jiang

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

jiangchenyangmail@163.com+86 571 8600 6811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026